

CSD/BSE&NSE/PR/2026-2027

June 17, 2026

To
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai – 400001

To
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400051

Scrip Code: 530239

Scrip Symbol: SUVEN

Dear Sir/Madam,

Sub: News Release

With reference to above subject, please find enclosed News Release of our company titled
**“Suvan Life Sciences announces Positive Topline results from Phase-2b clinical Proof-of-
Concept trial of Ropanicant for the treatment of Major Depressive Disorder”**

This is for your information and record.

Thanking you.
Yours faithfully,
For **Suvan Life Sciences Limited**

K. Sangeetha Laxmi
Company Secretary

Encl.: as above

Suvan Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 1152 Email: info@suvan.com website: www.suvan.com

News Release

Suven Life Sciences announces Positive Topline results from Phase-2b clinical Proof-of-Concept trial of Ropanicant for the treatment of Major Depressive Disorder.

**Ropanicant 45 mg twice daily treatment demonstrated clinically meaningful improvement in Montgomery–Åsberg Depression Rating Scale (MADRS), total score compared with placebo at Week 6, the primary endpoint.*

**The maximum likelihood (ML) - estimated mean difference from baseline versus placebo is -3.572 in the Full Analysis Set ($p = 0.038$), -3.570 in the modified Full Analysis Set ($p = 0.038$) and -4.067 in the Per-Protocol Set ($p = 0.023$).*

**Existing clinical evidence identifies a difference of approximately 2 points in MADRS total score versus placebo as clinically meaningful.*

**Evidence of treatment benefit was observed across secondary endpoints, including Clinical Global Impression–Severity of Illness (CGI-S) and the Sheehan Disability Scale (SDS), as well as the exploratory Quality of Life in Depression Scale.*

**Improvements in anhedonia correlated with improvements in measures of functioning and quality of life.*

**No withdrawal symptoms after discontinuation of Ropanicant treatment. No evidence of Dissociation.*

**Global Phase-3 registrational study in MDD is being planned.*

Hyderabad, India, 17-June-2026: Suven Life Sciences Limited, a clinical-stage biopharmaceutical company focused on discovering and developing innovative treatments for Central Nervous System (CNS) disorders, announced topline results from the Phase-2b clinical proof-of-concept trial of Ropanicant for Major Depressive Disorder (MDD). Ropanicant is an investigational nicotinic $\alpha 4\beta 2$ receptor antagonist in development as a potential treatment for patients with MDD.

The Phase-2b clinical trial demonstrated that twice daily oral administration of Ropanicant 45 mg resulted in a clinically meaningful change from baseline in Montgomery–Åsberg Depression Rating Scale (MADRS) total score at Week 6, the primary endpoint. The maximum likelihood (ML) - estimated mean difference from baseline versus placebo is -3.572 in the Full Analysis Set ($p = 0.038$), -3.570 in the modified Full Analysis Set ($p = 0.038$) and -4.067 in the Per-Protocol Set ($p = 0.023$). Evidence of treatment benefit of twice daily Ropanicant 45 mg was observed across secondary endpoints, including Clinical Global Impression–Severity of Illness (CGI-S; $p = 0.094$) and the Sheehan Disability Scale (SDS; $p = 0.039$), as well as the exploratory Quality of Life in Depression Scale (QLDS; $p = 0.068$).

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com

The baseline demographic and clinical characteristics were comparable across the placebo and Ropanicant treatment groups. The mean scores for depression severity (MADRS ~31), global illness severity (CGI-S ~4.3–4.5), functional impairment (Sheehan Disability Scale Total score ~19.6–21.2), quality of life (Quality of Life in Depression Scale Total score ~21.7–22.4), pleasure (Snaith-Hamilton Pleasure Scale Total score ~39.4–39.6), and depressive symptoms (Patient Health Questionnaire-9 Total score ~16.7) were similar across all groups, indicating a well-balanced study population at baseline.

Ropanicant was generally well tolerated in patients with MDD. The majority of treatment-emergent adverse events (TEAEs) reported during the study were mild to moderate in severity, with no unexpected safety signals identified. Most adverse events were transient in nature and resolved without clinically significant intervention.

Assessment of clinical laboratory parameters revealed no meaningful treatment-related changes and no patterns suggestive of adverse effects on haematology, clinical chemistry, or urinalysis evaluations. Likewise, there were no clinically relevant effects on electrocardiogram (ECG) parameters.

No clinically meaningful changes were identified in vital signs, including blood pressure, heart rate, respiratory rate, body weight, or body temperature. Physical examination findings remained generally unchanged throughout the study, with no treatment-related abnormalities or trends of clinical concern noted.

Overall, the safety and tolerability findings indicate that the Ropanicant was well tolerated, with no clinically meaningful effects on laboratory assessments, ECGs, vital signs, or physical examination findings, supporting its continued clinical development in patients with MDD.

“We are very excited to announce Ropanicant Phase-2b outcome, demonstrating clinically meaningful treatment benefits highlighting Ropanicant potential as a promising treatment for MDD. There is still a significant unmet medical need despite the availability of multiple approved therapies for MDD. We strongly believe that Ropanicant would offer differentiated treatment option to meet the unmet medical need” said Mr. Venkat Jasti, Chairman and Managing Director of Suven Life Sciences.

“MDD is the leading cause of disability worldwide, and approximately 50% of patients do not adequately benefit from standard first-line antidepressant therapies. The Phase-2b data strongly supports the potential of Ropanicant as a promising treatment for MDD. We look forward to engaging with regulatory authorities worldwide to discuss Phase-3 clinical development plans of Ropanicant” said Mr. Ramakrishna Nirogi, President and CSO of Suven Life Sciences.

Detailed findings from the clinical study will be presented in future medical conference and/or peer-reviewed journal publications.

On additional findings, use, method of treatment etc, “a priority patent application has already been filed and an International Application claiming priority from the priority application will be filed in a few days”.

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com

Ropanicant Phase-2b Study: The study is a randomized, double-blind, placebo-controlled trial that enrolled 214 patients across 35 sites for a treatment duration of six weeks. The trial was conducted exclusively in the United States of America. The study evaluated the efficacy and safety of Ropanicant 45 or 30 mg administered twice daily in patients with MDD, compared with placebo administered twice daily, in improving symptoms of depression as measured by the MADRS. For more information about the Phase-2b study visit ClinicalTrials.gov. Identifier NCT06836063.

About Ropanicant (SUVN-911): Ropanicant is a novel, selective nicotinic $\alpha 4\beta 2$ receptor antagonist in development for MDD. It has shown strong efficacy in animal models of depression and may address key limitations of current treatments, including rapid onset of action, reduced sexual dysfunction, and enhanced cognitive function. Non-clinical safety has been established through extensive pharmacology and toxicity studies (up to 9 months). In Phase-1 trials, Ropanicant was safe and well tolerated at the highest doses, with no significant effects from food or age. The Phase-2a trial demonstrated a favorable safety profile and significant improvements in depressive symptoms, as measured by the MADRS score. Suven fully owns all the intellectual property rights of Ropanicant.

About Suven Life Sciences: Suven Life Sciences Limited (Suven) is focused on the discovery and clinical development of innovative medicines that address unmet medical needs in CNS disorders. We have portfolio of advanced stage clinical candidates and research programs that are designed for CNS disorders such as Alzheimer's disease (AD), Sleep disorders, Major depressive disorders (MDD), Parkinson's disease (PD), Schizophrenia, Pain disorders, and Gastrointestinal disorders. Suven has 5 clinical stage assets across focus areas: Masupirdine (SUVN-502) for the treatment of agitation in patients with dementia of the Alzheimer's type (Global Phase-3 study ongoing); Samelisant (SUVN-G3031) for excessive daytime sleepiness (EDS) in narcolepsy (Phase-2 study for EDS completed; Phase-2 study for cataplexy and pivotal Phase-3 study for EDS are in planning); Ropanicant (SUVN-911) for MDD (Double blind randomized Placebo controlled Phase-2b study completed); Usmarapride (SUVN-D4010) for cognitive disorders (Phase-2 study in planning), SUVN-I6107 for cognitive disorders (Phase-1 study in progress). In addition to these clinical assets, we have 7 projects in research pipeline across multiple indications. Suven owns all intellectual property rights for its assets in all major markets.

For more information, please visit our website <http://www.suven.com>

Risk Statement: *Except for historical information, all the statements, expectations, and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve several risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances, and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.*

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com